BPC-157 vs TB-500: what's actually different?

Both compounds have substantial preclinical literatures and no completed human trials — a fact worth stating plainly, because online discussion often implies otherwise. BPC-157’s research base is almost entirely animal-model work, much of it from a single research group, though independent replications have grown. TB-500 borrows credibility from its parent molecule thymosin beta-4, which has genuine early-phase human trial history in wound and cardiac repair.

For researchers, that makes the pairing interesting precisely because the open questions differ: BPC-157’s literature needs replication breadth, TB-500’s needs fragment-specific data. The 1:1 combination — the “Wolverine stack” — exists because the two compounds’ proposed mechanisms are complementary rather than competing.